Iobenguane sulfate I-123

Identification

Name

Iobenguane sulfate I-123

Accession Number

DB09546

Description

Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

Type

Small Molecule

Groups

Approved, Investigational

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Iobenguane sulfate I-123 (DB09546)

×

Close

Weight

Average: 640.26
Monoisotopic: 639.953520274

Chemical Formula

C₁₆H₂₂I₂N₆O₄S

Synonyms

• Iobenguane sulfate I 123

Pharmacology

Indication

For use in the diagnostic imaging of adrenergically inervated tissues for the purposes of detecting metastatic pheochromocytoma or neuroblastoma [FDA Label]. Also used to assess the sympathetic inervation of the myocardium via determination of the heart to mediastinum ratio of radioactivity in patients with New York Heart Association class II or III heart failure.

Associated Conditions

• Neuroblastomas
• Pheochromocytomas
• Chronic heart failure with reduced ejection fraction (NYHA Class II)
• Chronic heart failure with reduced ejection fraction (NYHA Class III)

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

Iobenguane I-123 is taken up by and stored in adrenergic nerve terminals allowing for the radiographic imaging of adrenergically inervated organs and tissues [FDA Label].

Mechanism of action

Iobenguane I-123 is transported into adrenergic nerve terminals via the noradrenaline uptake transporter [FDA Label]. It is rapidly cleared from systemic circulation and collected in adrenergically invervated tissues. This allows for gamma-scintigraphic imaging of these tissues and their associated organs for diagnostic purposes.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Metabolized to m-iodohippuric acid and free radioiodide [FDA Label]. The metabolism of iobenguane I-123 and the enzymes involved has not been well studied.

Hover over products below to view reaction partners

• Iobenguane sulfate I-123
  • m-Iodohippuric acid
    • Radioiodide 123

Route of elimination

Primarily eliminated via the urine as the parent compound (70-90%) [FDA Label]. A small amount is eliminated in the urine as m-iodohippuric acid (</10%) and free radioiodide (</6%). Less than 1% is eliminated in the feces. Iobenguane I-123 is initially rapidly cleared from circulation follwed by a slow clearance from other tissues over 4 days. Retention is the longest in highly adrenergically inervated tissues like the adrenal medulla, heart, and salivary glands. Iobenguane I-123 is not cleared by dialysis.

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

As a radiopharmaceutical, iobenguane I-123 carries the risk of radiation toxicity if administered in innappropriately large doses or in patients with renal insufficency [FDA Label]. Fequent voiding of the bladder is encouraged to minimize the radiation dose to the bladder.

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Unlock Additional Data
Abacavir	Abacavir may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Acarbose	Acarbose may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Aceclofenac	Aceclofenac may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Acetaminophen	Acetaminophen may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Iobenguane sulfate I-123 which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Aclidinium	Aclidinium may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Acrivastine	Acrivastine may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.

Additional Data Available

Extended Description
Extended Description
Available for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
Available for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
Available for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
Available for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

No interactions found.

Products

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
i 123 MIBG meta iodobenzylguanidine	Injection, powder, lyophilized, for solution	25 mCi/1	Intravenous	Anazao Health Corporation	2012-05-23	Not applicable

Additional Data Available

Application Number
Application Number
Available for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
Available for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
i 123 MIBG meta iodobenzylguanidine	Iobenguane sulfate I-123 (25 mCi/1)	Injection, powder, lyophilized, for solution	Intravenous	Anazao Health Corporation	2012-05-23	Not applicable

Categories

Drug Categories

• Drugs that are Mainly Renally Excreted
• Radioactive Diagnostic Agent
• Radiopharmaceutical Activity

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as iodobenzenes. These are aromatic compounds containing one or more iodine atoms attached to a benzene.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Halobenzenes

Direct Parent

Iodobenzenes

Alternative Parents

Organic sulfuric acids / Aryl iodides / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Organopnictogen compounds / Organoiodides / Organic oxides / Hydrocarbon derivatives

Substituents

Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Carboximidamide / Guanidine / Hydrocarbon derivative / Iodobenzene / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxide

Molecular Framework

Not Available

External Descriptors

Not Available

Chemical Identifiers

UNII

23X1185WBO

CAS number

80663-95-2

InChI Key

XNACDNPGABUBFR-FKNPGSCZSA-N

InChI

InChI=1S/2C8H10IN3.H2O4S/c2*9-7-3-1-2-6(4-7)5-12-8(10)11;1-5(2,3)4/h2*1-4H,5H2,(H4,10,11,12);(H2,1,2,3,4)/i2*9-4;

IUPAC Name

bis(N-{[3-(¹²³I)iodophenyl]methyl}guanidine); sulfuric acid

SMILES

OS(O)(=O)=O.NC(=N)NCC1=CC([123I])=CC=C1.NC(=N)NCC1=CC([123I])=CC=C1

References

General References

Not Available

External Links

PubChem Compound

56840904

PubChem Substance

347827877

ChemSpider

32701571

RxNav

1427223

ChEMBL

CHEMBL3989523

FDA label

Download (302 KB)

MSDS

Download (100 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Intravenous	25 mCi/1

Prices

Not Available

Patents

Not Available

Properties

State

Liquid

Experimental Properties

Property	Value	Source
water solubility	Soluble	MSDS
Radioactivity (mCi/mL)	2	MSDS

Predicted Properties

Property	Value	Source
Water Solubility	0.1 mg/mL	ALOGPS
logP	1.42	ALOGPS
logP	1.69	ChemAxon
logS	-3.4	ALOGPS
pKa (Strongest Basic)	11.75	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	61.9 Å2	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	68.61 m3·mol-1	ChemAxon
Polarizability	21.91 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on November 30, 2015 12:10 / Updated on October 06, 2020 11:43